Application for admission

RNS Number : 2497B

Alliance Pharma PLC

31 March 2017

 

For immediate release

31 March 2017

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Application for admission

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that following the exercise of employee share options, application has been made by Alliance for a further 78,910 ordinary shares of 1p each in the Company ("Ordinary Shares") to be admitted to trading on AIM.

It is expected that these new Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares, will be admitted to trading on 6 April 2017.

After admission, Alliance will have 472,795,052 Ordinary Shares in issue.

For further information:

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive Andrew Franklin, Chief Financial Officer
Rob Bellhouse, Company Secretary
www.alliancepharma.co.uk
Buchanan	+ 44 (0) 20 7466 5000
Mark Court / Sophie Cowles / Jane Glover
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black / Toby Adcock

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

 

END

 

 

ALSLLFEEVRILVID